Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 13 Stocks Under $5 With High Upside Potential. On May 16, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), lowering the price target to $10 from $28.

Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?

A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform.

The firm released its updated outlook on the company after the latter released its fiscal Q1 2025 results. AbCellera Biologics Inc. (NASDAQ:ABCL) reported $4.2 million in total revenue for the quarter, generating a net loss of $45.6 million compared to net loss of $40.6 million last year. It also reached a cumulative total of 97 partner-initiated program starts with downstreams.

The analyst told investors in a research note that the firm is continuing to have a positive outlook for AbCellera Biologics Inc. (NASDAQ:ABCL), citing the continued execution of its wholly owned clinical pipeline.

Since the company is shifting the focus of its hybrid business model to a clinical-stage biotech, the firm updated its discount rate to account for the transition.

AbCellera Biologics (NASDAQ:ABCL) solves antibody discovery problems by integrating data science, technology, infrastructure, and interdisciplinary teams. It develops and discovers antibody medicines for indications across therapeutic areas, including metabolic and endocrine conditions, cancer, and autoimmune disorders. It boasts technology platforms that unlock drug classes, modalities, and targets, including T-cell engagers, peptide-MHCs, and transmembrane proteins.

While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.